Veliparib for the treatment of ovarian cancer

Expert Opinion on Investigational Drugs
Stefano BoglioloBarbara Gardella

Abstract

Ovarian cancer represents the sixth most commonly diagnosed cancer among women, with an incidence of 6.1 cases per 100.000 women and a cumulative lifetime risk of 0.5%. Treatment is based on debulking surgery and platinum-based chemotherapy, with the potential combination with taxane. However, the recently available data on the genetic basis and aetiology of ovarian cancer has led to the development of new anticancer drugs. Poly(ADP-ribose) polymerase (PARP) inhibitors are one of the most promising new classes of targeted agents currently under investigation for the treatment of ovarian cancer. Veliparib is a small molecule that inhibits both PARP-1 and PARP-2 and was originally shown to be efficacious in BRCA-associated tumors. This manuscript reviews the Phase I and II studies investigating the use of veliparib in ovarian cancer. This article also provides and discusses the pharmacokinetics and pharmacodynamics of veliparib. It is still being discussed whether PARP inhibitors should be used in a front-line or relapsed setting, alone or in combination with cytotoxic chemotherapy or as maintenance treatment. In terms of veliparib, further investigations are needed to explore its full potential in ovarian cancer. It is hoped tha...Continue Reading

References

Nov 1, 1990·Biological Reviews of the Cambridge Philosophical Society·T Alderson
Aug 1, 1989·British Journal of Obstetrics and Gynaecology·J H Shepherd
Aug 24, 1999·The Biochemical Journal·D D'AmoursG G Poirier
May 5, 2000·The Cochrane Database of Systematic Reviews·L Stewart, UNKNOWN Advanced Ovarian Cancer Trialists Group
Sep 12, 2002·Pharmacological Reviews·László Virág, Csaba Szabó
Feb 11, 2004·Clinical Oncology : a Journal of the Royal College of Radiologists·A J Chalmers
Jul 27, 2004·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Jean-Christophe AméGilbert de Murcia
May 4, 2005·Cellular and Molecular Life Sciences : CMLS·E PetermannS L Oei
May 3, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Cherrie K DonawhoDavid J Frost
May 17, 2007·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jeffrey M AlbertBo Lu
Feb 22, 2008·CA: a Cancer Journal for Clinicians·Ahmedin JemalMichael J Thun
Apr 15, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Shivaani KummarJames H Doroshow
Jun 26, 2009·The New England Journal of Medicine·Peter C FongJohann S de Bono
Jan 6, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Benjamin R TanHoward L McLeod
Feb 9, 2011·Proceedings of the National Academy of Sciences of the United States of America·Anand G PatelScott H Kaufmann
Mar 26, 2011·Drug Metabolism and Disposition : the Biological Fate of Chemicals·Xiaofeng LiYanbin Lao
Dec 1, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xuesong LiuAlexander R Shoemaker
Feb 1, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Anand G PatelScott H Kaufmann
Feb 7, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shivaani KummarJames H Doroshow
Mar 29, 2012·The New England Journal of Medicine·Jonathan LedermannUrsula Matulonis
Sep 21, 2012·Cancer Discovery·Matthew J SchiewerKaren E Knudsen
Nov 6, 2013·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Oriana YuLaurent Azoulay
Dec 21, 2013·Molecular Cancer Therapeutics·Junko MuraiYves Pommier
Jan 24, 2014·Clinical Pharmacokinetics·Ahmed Hamed SalemNael M Mostafa
Mar 13, 2014·Gynecologic Oncology·Joyce F LiuUrsula A Matulonis
Jun 21, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Jing LiPatricia LoRusso
Oct 31, 2014·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Kim A ReissNilofer S Azad
Dec 2, 2014·Cell Reports·Elizabeth StewartMichael A Dyer
Jan 16, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Shivaani KummarJames H Doroshow
Feb 25, 2015·Maturitas·Shifalika TangutooriSrinivas Sridhar
Jul 19, 2015·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Geoffrey KimRichard Pazdur
Aug 8, 2015·OncoTargets and Therapy·Lars M Wagner

❮ Previous
Next ❯

Citations

Sep 29, 2019·The New England Journal of Medicine·Robert L ColemanMichael A Bookman
Jun 17, 2020·Expert Opinion on Investigational Drugs·Giulio EvangelistiSimone Ferrero

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anthelmintics

Anthelmintics or antihelminthics are a group of antiparasitic drugs that expel parasitic worms (helminths) and other internal parasites from the body by either stunning or killing them and without causing significant damage to the host. Discover the latest research on anthelmintics here.

© 2021 Meta ULC. All rights reserved